Date: 2013-03-05
Type of information:
phase: preclinical
Announcement: presentation of results at the Alzheimer and Parkinson\'s diseases (AD/PD) conference held March 6th-10th in Florence
Company: Roche (Switzerland) reMYND (Belgium)
Product: BACE inhibitor R7921 and anti-Abeta-antibody gantenerumab
Action mechanism: BACE inhibitor R7921 and anti-Abeta-antibody gantenerumab
Disease: Alzheimer\'s disease
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On March 5, 2013, reMYND has announced that Bernd Bohrmann (Neuroscience, Roche) is presenting preclinical efficacy data at the Alzheimer and Parkinson\'s diseases (AD/PD) conference held March 6th-10th in Florence, on a novel combination therapy tested in an Alzheimer mouse model in collaboration with reMYND’s Contract Research Organization (CRO). This reMYND’s proprietary APP-London mouse model recapitulates important pathological and clinical hallmarks of Alzheimer’s disease. It can be used to evaluate Abeta directed approaches in general and to test beta-secretase inhibitor/modulator approaches in particular.
The treatment under investigation combined Roche’s BACE inhibitor R7921 and anti-Abeta-antibody gantenerumab, both currently in clinical development. The combination therapy efficiently reduced brain pathology, in particular amyloid plaque burden, even below levels at study start, which suggests clearance of pre-existing pathology and effective prevention of new pathology formation, suggesting that combining BACE inhibitor R7129 with gantenerumab may offer enhanced clinical efficacy to treat Alzheimer\'s disease.
